Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Hemophilia Treatment Market

Hemophilia Treatment Market Trends

Report ID: GMI2772
Published Date: Feb 2022
Report Format: PDF

Download Free Sample

Hemophilia Treatment Market Trends

The increasing prevalence of hemophilia contributing to the rising demand for treatment options is one of the prime factors driving the hemophilia treatment market expansion. Severe patients need a regular hemophilia treatment regimen to maintain enough clotting factors in the bloodstream to prevent bleeds. As per the Centers for Disease Control and Prevention, hemophilia A affects 1 in 5,000 male births each year in the U.S. This considerable prevalence is set to dramatically impact the market, since the number of dependent patients requiring quality care is increasing. Moreover, patients that receive proper care are expected to develop fewer co-morbid conditions and experience a lower risk of severe bleeding. Thus, the continuously increasing patient number has significantly boosted the demand for hemophilia treatment that in turn will uplift the product adoption rate.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for hemophilia treatment exceeded $11.1 billion in 2021 and is predicted to record around 5% CAGR over 2022-2028.

Hemophilia A captured a dominant revenue share of 82% in the global hemophilia treatment market in 2021 due to the rising occurrence of hypertension in patients diagnosed with hemophilia A.

Recombinant factor concentrates may witness a CAGR of 5% in the global hemophilia treatment market through 2028 as they have several advantages, including high quality safety profile and reduced risk of formation of alloantibodies against recombinant factor VIII in treated patients with hemophilia A.

The non-factor replacement therapy accounted for over $1.6 billion in the overall industry in 2021 and is anticipated to observe more than 21.3% CAGR through 2028 due to its benefits, such as increasing the ability to deliver prophylaxis to patients and reducing the burden of hemophilia treatment.